Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from OS Therapies Incorporated ( (OSTX) ).
On August 15, 2025, OS Therapies Incorporated‘s Board of Directors approved an amendment to the company’s bylaws, changing the quorum requirement for stockholder meetings to one-third of the voting power of outstanding shares. This amendment aims to streamline decision-making processes by allowing a smaller proportion of shareholders to constitute a quorum, potentially impacting the company’s governance and stakeholder engagement.
The most recent analyst rating on (OSTX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.
Spark’s Take on OSTX Stock
According to Spark, TipRanks’ AI Analyst, OSTX is a Underperform.
OS Therapies Incorporated faces significant financial difficulties, marked by increasing net losses, negative cash flows, and reliance on external financing. The technical analysis indicates bearish momentum with the stock trading below its moving averages. Valuation is challenging with no earnings to support a P/E ratio or dividend yield. These factors contribute to a low overall stock score, reflecting the company’s financial instability and negative market sentiment.
To see Spark’s full report on OSTX stock, click here.
More about OS Therapies Incorporated
Average Trading Volume: 504,004
Technical Sentiment Signal: Buy
Current Market Cap: $67.99M
For an in-depth examination of OSTX stock, go to TipRanks’ Overview page.